Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

- PMLiVE

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

The company expects overall earnings growth to be around 8% this year

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

J&J pushes to expand Imbruvica label after clinical success

Eyes the frontline setting in chronic lymphocytic leukaemia

- PMLiVE

FDA delays decision on Intercept’s NASH drug by three months

Action date pushed back to 26 June

- PMLiVE

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Outperformed rival across all primary and secondary endpoints

- PMLiVE

AbbVie creates new aesthetics division amid Allergan takeover

New separate business unit will operate own R&D functions

- PMLiVE

Allergan gets FDA nod for first oral CGRP drug for migraine

Extended use into acute treatment of migraine

- PMLiVE

J&J taps TARIS Biomedical for novel bladder cancer technology

Takes a bigger stake in the bladder cancer market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links